Tiotropium (Spiriva) Drug Class
Tiotropium belongs to the long-acting muscarinic antagonist (LAMA) class of medications, also referred to as long-acting anticholinergics.
Mechanism of Action
Tiotropium is an anticholinergic bronchodilator with specificity for muscarinic receptors 1. The drug works by:
- Binding to M2 and M3 muscarinic receptors in the airways 2
- Inhibiting acetylcholine release at the receptor level, preventing bronchoconstriction 2
- Producing prolonged bronchodilation through M3 receptor antagonism at airway smooth muscle 3
- Demonstrating higher receptor affinity than short-acting antimuscarinics like ipratropium, with prolonged M3 receptor binding compared to other LAMAs 4
Clinical Context
The LAMA class represents a cornerstone of maintenance therapy:
For COPD: LAMAs are recommended as initial treatment for GOLD groups B, C, and D 5. Tiotropium specifically improves lung function, reduces exacerbations, and decreases hospitalizations compared to placebo 2. When compared head-to-head with long-acting β-agonists (LABAs), tiotropium demonstrates superior exacerbation prevention (OR 0.86,95% CI 0.79-0.93) 2.
For Asthma: Tiotropium is approved as add-on therapy to inhaled corticosteroids with or without LABAs in patients with symptomatic asthma 3. The bronchodilatory effects are dose-dependent and last at least 24 hours 3.
Important Distinction
While tiotropium is chemically a quaternary ammonium anticholinergic compound 1, the clinically relevant classification is long-acting muscarinic antagonist (LAMA) to distinguish it from:
- Short-acting muscarinic antagonists (SAMAs) like ipratropium
- Other bronchodilator classes like LABAs or methylxanthines
The "long-acting" designation reflects its once-daily dosing and 24-hour duration of action, which differentiates it from short-acting anticholinergics in both mechanism duration and clinical application 6.